Unravelling the Proteomic Landscape of Imipenem Resistance in Pseudomonas aeruginosa: A Comparative Investigation between Clinical and Control Strains
Marius EidsaaiD, Animesh SharmaiD, Markus JanaschiD, Alicja KuchiD, Anna SkoczyńskaiD, Francesca Di BartolomeoiD
Abstract
The increasing prevalence of antimicrobial resistance (AMR) poses a significant challenge to global health, particularly with bacterial pathogens such as Pseudomonas aeruginosa, a notorious cause of nosocomial infections. This study focuses on the comparative proteomic analysis of an imipenem-resistant strain of P. aeruginosa, a representative of world epidemic clone ST235, and a wildtype control strain, P. aeruginosa ATCC 27853, in response to varying concentrations of imipenem. Using label-free quantification (LFQ) and gene ontology (GO) enrichment analyses, we identified significant differences in the proteomic responses between the two strains (data available via ProteomeXchange with identifier PXD055744.). The clinical strain exhibited a stable proteomic profile across the imipenem gradient, suggesting pre-established and efficient resistance mechanisms that do not require extensive reconfiguration under antibiotic pressure. In contrast, the control strain showed a broader, more reactive proteomic response, particularly in proteins associated with membrane transport, stress response, and biofilm formation. Notably, uncharacterized proteins were significantly upregulated in the clinical strain, indicating potential novel resistance mechanisms. These findings highlight the distinct strategies employed by the two strains, with the clinical strains stable resistance mechanisms contrasting sharply with the control strains reactive approach. The study underscores the importance of further research into the uncharacterized proteins that may play crucial roles in antibiotic resistance, potentially leading to new therapeutic targets in the fight against AMR. HighlightsO_LIStable resistance mechanisms: The clinical strain of Pseudomonas aeruginosa (ST235) exhibited a stable proteomic profile across varying concentrations of imipenem, indicating pre-established and efficient resistance mechanisms. C_LIO_LIReactive proteomic response: The control strain (P. aeruginosa ATCC 27853) showed a broader and more reactive proteomic response, particularly in proteins related to membrane transport, stress response, and biofilm formation. C_LIO_LIUncharacterized proteins: Significant upregulation of uncharacterized proteins in the clinical strain suggests potential novel resistance mechanisms that warrant further investigation. C_LI
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 22th percentile
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Responses of carbapenemase-producing and non-producing carbapenem-resistant Pseudomonas aeruginosa strains to meropenem revealed by quantitative tandem mass spectrometry proteomics
F. Salva-Serra, D. Jaen-Luchoro, … R. Karlsson·bioRxiv·Oct 23, 2022
- Analysis of antibiotic response in Clinical Wound Pseudomonas aeruginosa isolates: Unveiling Proteome Dynamics of tobramycin tolerant phenotype
Kasandra Buchholtz, Rosa Jersie-Christensen, … Biljana Mojsoska·Molecular & Cellular ProteomicsPeer-reviewed·Oct 16, 2024
- Diverse transcriptomic effects of evolved imipenem-relebactam resistance in Pseudomonas aeruginosa
Adeline Supandy, Ava J Dorazio, … Daria Van Tyne·bioRxiv·Sep 15, 2026
- Genome-Wide in silico analysis reveals activation of a silent resistome driving imipenem resistance in Pseudomonas aeruginosa
Sarfraz Anwar, A R Aromal, … Sintu Kumar Samanta·bioRxiv·Aug 29, 2026
- Multi-omics profiling of cross-resistance between ceftazidime-avibactam and meropenem identifies common and strain-specific mechanisms in Pseudomonas aeruginosa clinical isolates
Bartosz Jan Bartmanski, Anja Bösch, … Baharak Babouee Flury·mBioPeer-reviewed·Jun 4, 2025
- The Overexpression of AmpC is Not Required but May Contribute to Imipenem/Relebactam Non-susceptibility
S. Freed, N. D. Hanson·bioRxiv·Aug 15, 2023